Yin Cao1, Reiko Nishihara2, Kana Wu3, Molin Wang4, Shuji Ogino5, Walter C Willett6, Donna Spiegelman7, Charles S Fuchs8, Edward L Giovannucci6, Andrew T Chan9. 1. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts2Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston3Division of Gastroenterology, Massachusetts General. 2. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts4Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 5Department of Biostatistics, Harvard T. H. Chan School of Public Heal. 3. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 5Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 6Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts7Department of Pathology, Brigham and Women's Hosp. 6. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts4Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 8Channing Division of Network Medicine, Brigham and Women's Hospital a. 7. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 8. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts8Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 9. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston3Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston8Channing Division of Network Medicine, Brigham.
Abstract
IMPORTANCE: The US Preventive Services Task Force recently recommended the use of aspirin to prevent colorectal cancer and cardiovascular disease among many US adults. However, the association of aspirin use with the risk for other cancer types and the potential population-wide effect of aspirin use on cancer, particularly within the context of screening, remain uncertain. OBJECTIVES: To examine the potential benefits of aspirin use for overall and subtype-specific cancer prevention at a range of doses and durations of use and to estimate the absolute benefit of aspirin in the context of screening. DESIGN, SETTING, AND PARTICIPANTS: Two large US prospective cohort studies, the Nurses' Health Study (1980-2010) and Health Professionals Follow-up Study (1986-2012), followed up 135 965 health care professionals (88 084 women and 47 881 men, respectively) who reported on aspirin use biennially. The women were aged 30 to 55 years at enrollment in 1976; the men, aged 40 to 75 years in 1986. Final follow-up was completed on June 30, 2012, for the Nurses' Health Study cohort and January 31, 2010, for the Health Professionals Follow-up Study cohort, and data were accessed from September 15, 2014, to December 17, 2015. MAIN OUTCOMES AND MEASURES: Relative risks (RRs) for incident cancers and population-attributable risk (PAR). RESULTS: Among the 88 084 women and 47 881 men who underwent follow-up for as long as 32 years, 20 414 cancers among women and 7571 cancers among men were documented. Compared with nonregular use, regular aspirin use was associated with a lower risk for overall cancer (RR, 0.97; 95% CI, 0.94-0.99), which was primarily owing to a lower incidence of gastrointestinal tract cancers (RR, 0.85; 95% CI, 0.80-0.91), especially colorectal cancers (RR, 0.81; 95% CI, 0.75-0.88). The benefit of aspirin on gastrointestinal tract cancers appeared evident with the use of at least 0.5 to 1.5 standard aspirin tablets per week; the minimum duration of regular use associated with a lower risk was 6 years. Among individuals older than 50 years, regular aspirin use could prevent 33 colorectal cancers per 100 000 person-years (PAR, 17.0%) among those who had not undergone a lower endoscopy and 18 colorectal cancers per 100 000 person-years (PAR, 8.5%) among those who had. Regular aspirin use was not associated with the risk for breast, advanced prostate, or lung cancer. CONCLUSIONS AND RELEVANCE: Long-term aspirin use was associated with a modest but significantly reduced risk for overall cancer, especially gastrointestinal tract tumors. Regular aspirin use may prevent a substantial proportion of colorectal cancers and complement the benefits of screening.
IMPORTANCE: The US Preventive Services Task Force recently recommended the use of aspirin to prevent colorectal cancer and cardiovascular disease among many US adults. However, the association of aspirin use with the risk for other cancer types and the potential population-wide effect of aspirin use on cancer, particularly within the context of screening, remain uncertain. OBJECTIVES: To examine the potential benefits of aspirin use for overall and subtype-specific cancer prevention at a range of doses and durations of use and to estimate the absolute benefit of aspirin in the context of screening. DESIGN, SETTING, AND PARTICIPANTS: Two large US prospective cohort studies, the Nurses' Health Study (1980-2010) and Health Professionals Follow-up Study (1986-2012), followed up 135 965 health care professionals (88 084 women and 47 881 men, respectively) who reported on aspirin use biennially. The women were aged 30 to 55 years at enrollment in 1976; the men, aged 40 to 75 years in 1986. Final follow-up was completed on June 30, 2012, for the Nurses' Health Study cohort and January 31, 2010, for the Health Professionals Follow-up Study cohort, and data were accessed from September 15, 2014, to December 17, 2015. MAIN OUTCOMES AND MEASURES: Relative risks (RRs) for incident cancers and population-attributable risk (PAR). RESULTS: Among the 88 084 women and 47 881 men who underwent follow-up for as long as 32 years, 20 414 cancers among women and 7571 cancers among men were documented. Compared with nonregular use, regular aspirin use was associated with a lower risk for overall cancer (RR, 0.97; 95% CI, 0.94-0.99), which was primarily owing to a lower incidence of gastrointestinal tract cancers (RR, 0.85; 95% CI, 0.80-0.91), especially colorectal cancers (RR, 0.81; 95% CI, 0.75-0.88). The benefit of aspirin on gastrointestinal tract cancers appeared evident with the use of at least 0.5 to 1.5 standard aspirin tablets per week; the minimum duration of regular use associated with a lower risk was 6 years. Among individuals older than 50 years, regular aspirin use could prevent 33 colorectal cancers per 100 000 person-years (PAR, 17.0%) among those who had not undergone a lower endoscopy and 18 colorectal cancers per 100 000 person-years (PAR, 8.5%) among those who had. Regular aspirin use was not associated with the risk for breast, advanced prostate, or lung cancer. CONCLUSIONS AND RELEVANCE: Long-term aspirin use was associated with a modest but significantly reduced risk for overall cancer, especially gastrointestinal tract tumors. Regular aspirin use may prevent a substantial proportion of colorectal cancers and complement the benefits of screening.
Authors: Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs Journal: JAMA Date: 2005-08-24 Impact factor: 56.272
Authors: J E Manson; M J Stampfer; G A Colditz; W C Willett; B Rosner; F E Speizer; C H Hennekens Journal: JAMA Date: 1991 Jul 24-31 Impact factor: 56.272
Authors: Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade Journal: Lancet Date: 2010-12-06 Impact factor: 79.321
Authors: J Cuzick; M A Thorat; C Bosetti; P H Brown; J Burn; N R Cook; L G Ford; E J Jacobs; J A Jankowski; C La Vecchia; M Law; F Meyskens; P M Rothwell; H J Senn; A Umar Journal: Ann Oncol Date: 2014-08-05 Impact factor: 32.976
Authors: Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino Journal: J Clin Oncol Date: 2017-04-13 Impact factor: 44.544
Authors: Keming Yang; Xin Li; Michele R Forman; Patrick O Monahan; Bret H Graham; Amit Joshi; Mingyang Song; Dong Hang; Shuji Ogino; Edward L Giovannucci; Immaculata De Vivo; Andrew T Chan; Hongmei Nan Journal: Carcinogenesis Date: 2019-12-31 Impact factor: 4.944
Authors: Guillaume Onyeaghala; Anna K Lintelmann; Corrine E Joshu; Pamela L Lutsey; Aaron R Folsom; Kimberly Robien; Elizabeth A Platz; Anna E Prizment Journal: Cancer Date: 2019-12-24 Impact factor: 6.860
Authors: P M Webb; R Na; E Weiderpass; H O Adami; K E Anderson; K A Bertrand; E Botteri; T M Brasky; L A Brinton; C Chen; J A Doherty; L Lu; S E McCann; K B Moysich; S Olson; S Petruzella; J R Palmer; A E Prizment; C Schairer; V W Setiawan; A B Spurdle; B Trabert; N Wentzensen; L Wilkens; H P Yang; H Yu; H A Risch; S J Jordan Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: E Susan Amirian; Quinn T Ostrom; Georgina N Armstrong; Rose K Lai; Xiangjun Gu; Daniel I Jacobs; Ali Jalali; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen M Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Robert B Jenkins; Daniel H Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Christoffer Johansen; Richard S Houlston; Michael E Scheurer; Sanjay Shete; Christopher I Amos; Beatrice Melin; Melissa L Bondy Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-27 Impact factor: 4.254
Authors: Ying Zhu; Yongyue Wei; Ruyang Zhang; Xuesi Dong; Sipeng Shen; Yang Zhao; Jianling Bai; Demetrius Albanes; Neil E Caporaso; Maria Teresa Landi; Bin Zhu; Stephen J Chanock; Fangyi Gu; Stephen Lam; Ming-Sound Tsao; Frances A Shepherd; Adonina Tardon; Ana Fernández-Somoano; Guillermo Fernandez-Tardon; Chu Chen; Matthew J Barnett; Jennifer Doherty; Stig E Bojesen; Mattias Johansson; Paul Brennan; James D McKay; Robert Carreras-Torres; Thomas Muley; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboeller; Albert Rosenberger; Gad Rennert; Walid Saliba; Susanne M Arnold; John K Field; Michael P A Davies; Michael W Marcus; Xifeng Wu; Yuanqing Ye; Loic Le Marchand; Lynne R Wilkens; Olle Melander; Jonas Manjer; Hans Brunnström; Rayjean J Hung; Geoffrey Liu; Yonathan Brhane; Linda Kachuri; Angeline S Andrew; Eric J Duell; Lambertus A Kiemeney; Erik Hfm van der Heijden; Aage Haugen; Shanbeh Zienolddiny; Vidar Skaug; Kjell Grankvist; Mikael Johansson; Penella J Woll; Angela Cox; Fiona Taylor; Dawn M Teare; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Richard S Houlston; John McLaughlin; Victoria L Stevens; Hongbing Shen; Zhibin Hu; Juncheng Dai; Christopher I Amos; Younghun Han; Dakai Zhu; Gary E Goodman; Feng Chen; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-01-30 Impact factor: 4.254
Authors: Tracey G Simon; Yanan Ma; Jonas F Ludvigsson; Dawn Q Chong; Edward L Giovannucci; Charles S Fuchs; Jeffrey A Meyerhardt; Kathleen E Corey; Raymond T Chung; Xuehong Zhang; Andrew T Chan Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777